SynCore Biotechnology Co Ltd
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the trea… Read more
SynCore Biotechnology Co Ltd (4192) - Net Assets
Latest net assets as of September 2025: NT$257.97 Million TWD
Based on the latest financial reports, SynCore Biotechnology Co Ltd (4192) has net assets worth NT$257.97 Million TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$272.85 Million) and total liabilities (NT$14.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$257.97 Million |
| % of Total Assets | 94.55% |
| Annual Growth Rate | -11.02% |
| 5-Year Change | -47.43% |
| 10-Year Change | N/A |
| Growth Volatility | 23.73 |
SynCore Biotechnology Co Ltd - Net Assets Trend (2015–2024)
This chart illustrates how SynCore Biotechnology Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SynCore Biotechnology Co Ltd (2015–2024)
The table below shows the annual net assets of SynCore Biotechnology Co Ltd from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$294.69 Million | -17.49% |
| 2023-12-31 | NT$357.14 Million | +43.42% |
| 2022-12-31 | NT$249.01 Million | -43.78% |
| 2021-12-31 | NT$442.92 Million | -20.99% |
| 2020-12-31 | NT$560.58 Million | -8.41% |
| 2019-12-31 | NT$612.03 Million | -13.40% |
| 2018-12-31 | NT$706.70 Million | -1.93% |
| 2017-12-31 | NT$720.61 Million | -25.43% |
| 2016-12-31 | NT$966.36 Million | +14.66% |
| 2015-12-31 | NT$842.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SynCore Biotechnology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 12787300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$348.97 Million | 118.42% |
| Total Equity | NT$294.69 Million | 100.00% |
SynCore Biotechnology Co Ltd Competitors by Market Cap
The table below lists competitors of SynCore Biotechnology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dr. Phone Fix Canada Corporation
V:DPF
|
$7.59 Million |
|
Gagasan Nadi Cergas Berhad
KLSE:0206
|
$7.59 Million |
|
AnorTech Inc.
V:ANOR
|
$7.59 Million |
|
GFL Limited
NSE:GFLLIMITED
|
$7.59 Million |
|
Xbrane Biopharma AB
ST:XBRANE
|
$7.58 Million |
|
Briacell Therapeutics Corp
NASDAQ:BCTX
|
$7.58 Million |
|
Elgi Rubber Company Limited
NSE:ELGIRUBCO
|
$7.58 Million |
|
Beyond Air Inc
NASDAQ:XAIR
|
$7.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SynCore Biotechnology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 357,136,000 to 294,688,000, a change of -62,448,000 (-17.5%).
- Net loss of 54,283,000 reduced equity.
- Other factors decreased equity by 8,165,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-54.28 Million | -18.42% |
| Other Changes | NT$-8.16 Million | -2.77% |
| Total Change | NT$- | -17.49% |
Book Value vs Market Value Analysis
This analysis compares SynCore Biotechnology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.49x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 2.03x to 2.49x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$10.31 | NT$20.90 | x |
| 2018-12-31 | NT$8.48 | NT$20.90 | x |
| 2019-12-31 | NT$6.29 | NT$20.90 | x |
| 2020-12-31 | NT$19.84 | NT$20.90 | x |
| 2021-12-31 | NT$14.36 | NT$20.90 | x |
| 2022-12-31 | NT$8.10 | NT$20.90 | x |
| 2023-12-31 | NT$11.14 | NT$20.90 | x |
| 2024-12-31 | NT$8.38 | NT$20.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SynCore Biotechnology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -232.60%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.08x
- Recent ROE (-18.42%) is above the historical average (-46.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -21.61% | -1178.09% | 0.02x | 1.22x | NT$-266.44 Million |
| 2016 | -16.79% | -2351.97% | 0.01x | 1.15x | NT$-258.87 Million |
| 2017 | -35.80% | -3167.89% | 0.01x | 1.17x | NT$-330.05 Million |
| 2018 | -41.62% | -3816.86% | 0.01x | 1.14x | NT$-364.80 Million |
| 2019 | -66.77% | -3151.36% | 0.02x | 1.25x | NT$-469.84 Million |
| 2020 | -71.16% | -2991.29% | 0.01x | 1.63x | NT$-454.98 Million |
| 2021 | -103.54% | -6608.98% | 0.01x | 1.86x | NT$-502.89 Million |
| 2022 | -75.77% | -1189.80% | 0.04x | 1.75x | NT$-213.57 Million |
| 2023 | -10.69% | -189.01% | 0.05x | 1.06x | NT$-73.89 Million |
| 2024 | -18.42% | -232.60% | 0.07x | 1.08x | NT$-83.75 Million |
Industry Comparison
This section compares SynCore Biotechnology Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SynCore Biotechnology Co Ltd (4192) | NT$257.97 Million | -21.61% | 0.06x | $7.58 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |